Clinical Trial to Evaluate the Safety and Pharmacokinetic/Pharmacodynamic Characteristics of DW1903

Phase 1CompletedNCT05155072

Daewon Pharmaceutical Co., Ltd.31 enrolled

Overview

A Randomized, Open-label, Oral in healthy male volunteers

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Gastritis

Interventions

DW1903DRUG

DW1903

DW1903-R1DRUG

DW1903-R1

DW1903-R2DRUG

DW1903-R2

Eligibility

Sex: MALEMin age: 19 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Healthy Volunteers who are ≥19 years old * BMI between 18 and 30 kg/m2 * Body weight ≥50kg Exclusion Criteria: •Clinically significant Medical History

Locations (1)

Chungbuk National University Hospital

Cheongju-si, South Korea

Outcomes

Primary Outcomes

pH monitoring

Pharmacodynamic Endpoint

Time frame: up to day 5

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.